Point32Health challenges Aduhelm, threatens coverage for 1.1M members

(By Nick Moran for Becker’s Hospital Review)

Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless the price is reduced.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org